Introduction
Lipid transport between intracellular organelles is thought to involve carrier proteins. Several different lipid transfer proteins have been isolated which are involved in the transport of phosphatidylcholine, phosphatidylinositol, phosphatidylserine, cholesterol, gangliosides, glycolipids, dolichol and vitamin D3 [ 1-31. In addition to protein mediated transport, other processes, such as diffusion at membrane contact sites and spontaneous transfer between membranes, are thought to occur [l-51. This review primarily deals with steroVcholesterol transport proteins in mammalian cells. In spite of the tremendous amount of information available regarding extracellular cholesterol transport, there is a paucity of information with regard to intracellular cholesterol transport. In this review, we present evidence relating to transport, utilization and synthesis of cholesterol via the participation of one such intracellular transport protein, namely sterol carrier protein-2 (SCP-2). We hope that this review will stimulate further study in a field that has shown considerable progress in the last few years.
Physiological role of SCP-2 in cholesterol metabolism
In the last decade, several investigators have provided evidence that SCP-2 participates in cholesterol metabolism [ 1-51, In in vitro studies, SCP-2 activates the microsomal conversion of lanosterol to cholesterol. A'-cholesten-.?P-ol to 7dehydrocholes-terol and 7-dehydrocholesterol to cholesterol [ 3-61, The stimulation of sterol-A'-reductase follows hyperbolic kinetics and has a K,,, for SCP-2 of 0.16 ,u\[ [4-f) ]. Evidence has also been presented that SCP-2 stimulates the corresponding enzyme by binding the sterol and donating it to the membrane bound enzymes [ 4-6 1.
SCP-2 is also knou n t o be involved in cholesterol utilization and transport. Cholesterol is converted t o cholesterol ester by acyl-CoA cholesterol acyl transferase (ACA?'), t o 7a-hydroxycholesterol by 7a-hydroxylase (both are microsomal enzymes) and to pregnenolone by the mitochondria1 cholesterol cytochrome P450 side-chain cleavage enzyme system. All of these processes are known t o be markedly stimulated by 3, 4, 5, 71. Recently, it was shown that co-transfections of cDNAs coding for SCP-2, adrenodoxin and the side-chain cleavage enzyme in COS-7 kidney cells resulted in 5-fold higher levels of steroid hormone synthesis when compared with cells transfected with the side-chain cleavage enzyme and adrenodoxin only 181. Similar evidence was provided by liposomal fusion experiments using intact adrenal cells. Addition of rabbit anti-rat SCP-2 antibody inhibited ;idrenocorticotro~~liic hormone ( A U I 1) stimulated steroidogenesis 17 i. 'I'his inhibition was rescued by ;I second liposoiiml fusion with SCI'-2 Cholesterol may he transported to peroxisomes, smooth endoplasmic reticulum (SEK) and mitochondria in lipid droplets enriched in SCP-2 [ 1, 4, 5, 9-1 11. It is assunied that all of these processes require a binding of SCP-2 to the sterol, transport of the sterol to the appropriate organelle and eventual donation of the ligand to the appropriate membrane bound enzyme 12-31. In addition, SCP-2 has been shown in in vitro studies t o mediate the transfer of sterols, phospholipids, gangliosides and even stimulate the cis-prenyl transferase, a key enzyme in dolichol biosynthesis I 1 ~ 5, [12] [13] [14] [15] [16] , It remains to be unequivocally established if these additional in vitro activities occur in a physiological context. "1.
Primary sequence of SCP-2 as determined by protein and cDNA sequencing
The history of the discovery of sterol carrier proteins has been discussed extensively in previous reviews [ 1-51. Since the discovery of a requirenient for liver cytosol in cholesterol biosynthesis in the 1950s, both SCP-1 and SCP-2 have been purified [l-51. SCP-1 has a pI of 5.6 and a molecular mass of 47 kI>a [ 17, 1x1. SCP-I is required for the conversion of squalene to lanosterol by liver microsoma1 membranes. XI'-2 has been purified from bovine, rat, human, goat, chicken liver and ii rat hepatoma [ I , 4-6, 10, 
Protein sequence determination
Bovine liver SCP-2 is a single polypeptide chain of 121 amino acid residues with alanine at the carboxy terminus [ 13. Rat liver SCP-2 has been sequenced and is 123 amino acids long and has two additional residues (K-L) at its carboxy-terminus [3, 211 . The carboxy-terminal sequence A/S-K-L is known to be a peroxisomal targeting sequence . The Nterminus of SCP-2 has been shown to have considerable similarity (44%) to the substrate binding region of phosphatidyl choline transfer protein (PCTP). A model of the tertiary structure of SCP-2 has been proposed, based on similarities with adenylate kinase, PCTP and IgGs [21] . They proposed, based on the similarity of SCP-2 to PCTP and adenylate kinase, that residues 15-30 form an amphipathic a-helix that is postulated to bind phospholipids [21] . Residues 35-103, based upon similarity to the heavy chain of IgG, are thought to have six anti-parallel P-strands that form a P-barrel structure and are postulated to contain a sterol/ cholesterol binding site [2 11 . The single cysteine residue is thought to play a role in protein dimerization [l, 131. Recently, an SCP-2 like protein was isolated from chicken liver that, based on Western blots, corresponds to molecular masses of 12 kDa, 30-36 kDa and 55-60 kDa forms of the protein [20] . However, the amino acid composition of the protein (molecular mass, 12 kDa) and the amino terminal sequence were quite different from SCP-2. It remains to be seen if this protein is indeed the chicken homologue of mammalian SCP-2.
Isolation and sequencing of SCP-2 cDNA clones
Following the protein sequencing of SCP-2, several groups have isolated cDNA clones which suggest the existence of a family of SCP-2 like proteins. cDNA clones from rat, mouse and human have been sequenced [8, [22] [23] [24] [25] [26] [27] [28] [29] [30] . They code for proteins of molecular mass 13.2, 15.5, 30.8 and 58.9 kDa.
The SCP-2 gene has been localized to human Chromosome 1 (p21 -pterl) [24] . Mouse and rat liver SCP-2 has also been successfully expressed in Escherzchzh coli [4, 22, 31, S. Kesav and T. J. Scallen, unpublished observation] . We have expressed rat liver SCP-2 in E. coli by using an isopropylthiogalactoside (IPTG) inducible (lac promoter driven) periplasmic secretion vector [32] . As shown in Fig. 1, upon induction with 5 mM IPTG, large amounts of the protein ( 5 7 % of total protein) accumulate in the periplasmic space in E. coli over 6 h. The bacterially expressed proteins have been shown to be biologically active as measured by enhancement of sterol-A'-reductase and ACAT in vitro and by a fluorescent phospholipid transfer assay [22-3 11.
The cDNA clones from mouse, rat and human sources show considerable similarity [1] [2] [3] [4] [22] [23] [24] [25] [26] [27] [28] [29] [30] . One of these clones reveals the existence of an amino-terminal mitochondria1 targeting sequence (20 amino acids), coding for a protein of molecular mass 15.5 kDa [8, [22] [23] [24] [25] [26] [27] [28] [29] [30] . A carboxyterminal peroxisomal targeting sequence A-K-L is present in the cDNAs coding for proteins of molecular mass 13.2, 15.5, 30.8 and 58.9 kDa forms of SCP-2 [8,22-301. In the protein purified from rat liver, the carboxy-terminal leucine is absent [21] . In addition, the cDNAs that encode the higher molecular mass forms of the protein all encode the 13.2 kDa form of SCP-2 in the carboxy terminus [22-301. It is proposed from the evidence that the 1.0 kb and 1.7 kb forms of the mRNA transcript code for the 13.2, 15.5 and 30.8 kDa forms of SCP-2 [4, 8, [22] [23] [24] [25] [26] [27] [28] [29] [30] . The 2.2 and 2.7 kb mRNA transcripts encode a higher molecular weight form of SCP-2 of molecular mass 58.9 kDa [8, [22] [23] [24] [25] [26] [27] [28] [29] [30] . It is not clear, at this stage, if larger transcripts which may encode even larger forms of SCP-2 exist.
An intriguing observation is that there is a similarity between the SCP-X (58.9 kDa) protein and E. coli acetyl CoA transferase and rat mitochondrial and peroxisomal 3-oxoacyl The existence of a SCP-2-phospholipid complex has been demonstrated using fluorescent phospholipids [l, 131. It was postulated that SCP-2 has a non-specific phospholipid binding site [l, 15, 161. The evidence, however, points to a higher specificity, since the transfer of negatively charged phospholipids is preferred. It has also been shown that sterol transfer is enhanced considerably in the presence of negatively charged phospholipids such Volume 20 
Mechanism of action of SCP-2
Panels A and B show the formation of a ternary complex either as a cysteinyl dimer and two membranes (panel A) or as a monomer and two membranes (panel B). Panels C and D show the formation of a binary complex either as a cysteinyl dimer and one membrane (panel C) or as a monomer and one membrane (panel D). In both cases, an amphipathic a-helix is involved in docking with the membrane. A sterolkholesterol binding site is illustrated and the distance of tryptophan-50 from the sterol nucleus is shown to be 1.35 nm.
I
as phosphatidyl serine, phosphatidyl inositol and cardiolipin [ 39-4 11.
The evidence for the existence of a B-barrel type hydrophobic pocket in transport proteins has been shown for the phosphatidyl choline transfer protein, fatty acid binding protein and the serum retinol binding protein [ 1, 21. Since SCP-2 has not been crystallized, the precise nature of the phospholipid and the sterol binding hydrophobic pockets remains to be demonstrated. The characterization of a phospholipid interaction site in the N-terminal amphipathic a-helix and a P-barrel type sterol interaction site should prove to be a challenging area of study.
Mechanism of action of SCP-2
Several models have been proposed to explain how SCP-2 facilitates lipid transfer between membranes Fig. 1 , the amphipathic a-helix would facilitate docking to the membrane by electrostatic and hydrophobic interactions. As stated earlier, evidence for such a complex has been provided [2, 371 . A second possibility would be the formation of a ternary complex as shown in Fig. 2 . This would involve the docking of SCP-2 between two membranous structures either as a monomer or as a cysteinyl dimer thereby facilitating transfer as illustrated in Fig. 2, panels A was shown that peroxisomes and cytoplasmic lipid droplets (enriched in SCP-2) form a complex. A similar mechanism may occur in the transfer of cholesterol to mitochondria. The transport of cholesterol from peroxisomes to mitochondria by SCP-2 fused with lipid droplets has recently been reported [lo] . The signal sequences found in the various forms of SCP-2 could facilitate directional organelle targeting and transfer [l-41. The two mechanisms proposed here should prove to be an exciting area of study.
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Tissue and subcellular distribution of SCP-2
Tissue distribution
SCP-2 is a protein found in tissues which synthesize or metabolize cholesterol or which are involved in steroidogenesis. The largest amounts (0.4%) are found in the liver, adrenals and intestines [ 1-5, 71.
In addition, other endocrine tissues, e.g. testis (Leydig cells), ovary and corpus luteum, express significant quantities of SCP-2. Organs such as heart, kidney, lungs and spleen express moderate levels (0.06%) of 9, 10, 421 . A trace amount is also found in the adult brain [l-51.
Subcellular distribution
It has recently been shown that a large portion of SCP-2 is localized in peroxisomes and mitochondria [l, 9, 11, 421 . In a recent cytochemical study SCP-2 was immunolocalized in 15 nm peroxisomal particles and these particles were associated with intracytoplasmic lipid droplets which were also found to be enriched in SCP-2 [9, 101. Likewise, using anti-rat SCP-2 antibody and Protein A-colloidal gold techniques, peroxisomes were densely labelled in rat liver and adrenals [ll] . Density gradient analysis has confirmed that a peroxisomal form of the protein of molecular mass 58 kDa is membrane bound [ 1, 111. Pulse chase experiments have revealed that the protein (molecular mass 58 kDa, i.e. SCP-X) is not a precursor of molecular mass 13 kDa, i.e. SCP-2 [l] . The role of SCP-2 in peroxisomes and the SER is supported by the fact that a number of enzymes involved in cholesterol metabolism have been identified in peroxisomes and the SER [2, 4, [42] [43] [44] 
Regulation of SCP-2 gene expression
The cloning of cDNAs encoding various forms of SCP-2, i.e. the proteins of molecular mass 13.2, 15.5, 30.8 and 58.9 kDa, has facilitated the study of the regulation of gene expression of SCP-2. Numerous groups have shown, by Northern analysis, the existence of at least four mRNA transcripts of 1.0, 1.7, 2.2 and 2.7 kb which are expressed in most tissues. In the liver, adrenals and intestines, the 1.0 kb transcript is the most abundant [8, [22] [23] [24] [25] [26] [27] [28] [29] [30] . Likewise, there seems to be a tissue specificity in the manner in which the other transcripts are expressed [X, 22-30] . Moreover, it was shown that a 0.7 kb 3' extension could account for the 2.7 kb and the 1.7 kb transcripts, in comparison with the 2.2 kb and the 1.0 kb transcripts respectively [27] . It has also been suggested that these transcripts may be encoded by the same gene (30-45 kbp) and are perhaps generated by alternative splicing [4, 8, 22, 26, 281 . However, the existence of multiple genes and other SCP-2 like genes cannot be ruled out.
Recently, it was shown that treatment for 3 days with chorionic gonadotropin increased the levels of SCP-2 transcripts in the ovary by nearly 5-fold [44]. 8-Bromo-CAMP also increased the levels of the SCP-2 mRNA; synthesis of protein was inhibited by cycloheximide and actinomycin 1) [44] .
This indicates that CAMP-mediated SCP-2 expression may not necessarily be at the transcriptional level [44] . It correlates with immunoblot studies on protein translated in vitro from mRNA isolated from adrenocortical cells treated with . Likewise, it was shown that transcripts coding for the SCP-X proteins of molecular mass 30.8 kDa and 58.9 kDa increased dramatically during placental differentiation from cytotrophoblasts into syncytiotrophoblasts [24] . By immunoblot studies, it was also shown that lutein-
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izing hormone increases the levels of SCP-2 5-fold in Leydig cells [42] . Estradiol activates SCP-2 levels 3-fold in rat corpora lutea [3] . The SCP-2 gene is yet to be sequenced, but it is conceivable that many of these effects may be correlated with transcriptional (and also possibly post-transcriptional) events involving 5'-CAMP response elements. There also seems to be a sexual difference in the expression of SCP-2 and SCP-X (proteins of molecular mass 13.2 kDa and 58.9 kDa) in developing and adult mice [46] . It is possible that sequencing of the 5' flanking region of the SCP-2 gene may also reveal the existence of other response elements such as sterol response and steroid hormone elements. 
Role of SCP-2 in disease states

Future research
The physiological role of the SCP-2 family of proteins remains an enigma. The progress made in the last few years should facilitate studies of the physiological role of this protein. The identification of SCP-2 mutant cell lines should provide an insight into the function of SCP-2 in intracellular cholesterol transport and cholesterol metabolism. The availability of cDNAs and the fact that two groups have overexpressed SCP-2 protein in E. coli should facilitate X-ray cystallography, two-dimensional n.m.r. and structure/function studies that would elucidate the nature of the sterol and phospholipid binding sites. The sequencing of the SCP-2 gene would be a first step in understanding the regulation of SCP-2 gene expression. Last, but not the least, the role of SCP-2 in intracellular cholesterol transport-related defects requires investigation.
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Introduction I'eroxisome proliferators are a diverse group of chemicals which when administered to rats and mice produce liver hyperplasia and hypertrophy, the latter being predominantly due to an increase in the size and number of hepatic peroxisomes [l] . Interest in these chemicals stems from the observation that they are rodent liver carcinogens. In parAbbreviations used: I'I'AK. peroxisomc proliferator activated receptor; I'PKE. peroxisonie proliferator response clement; 1;ARI'. fatty acid binding protein. ' To whom correspondence should be addressed. ticular, they are not directly mutagenic and appear to use a novel carcinogenic mechanism. There are therefore two important research questions: how do peroxisome proliferators produce liver tumours in rodents such as rats and mice and what is the relevance of these findings to man?
The most potent peroxisome proliferators are hypolipidaemic drugs that were developed for the treatment of coronary heart disease [2] . These drugs lower circulating levels of cholesterol but are more effective at lowering triglycerides. They are therefore used to treat patients with type IV hyperlipidaemia who have high levels of circulating tri-
